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Abstract 
Background: Hypothyroidism is a thyroid gland-related disorder which causes lipid metabolism disturbance. 
Subclinical Hypothyroidism (SCH) is a compensatory stage in the course of this disease, in which TSH production 
increases while the levels of thyroid hormones are in normal or low-normal range. There are no studies about the 
lipid profile abnormalities in SCH. Therefore, the aim of this study was to evaluate the lipid profile in SCH patients 
and compare it with normal individuals. Materials and Methods: In this case-control study, subjects were 
randomly chosen among  800 individuals referred to Neka city hospital in Mazandaran province, Iran in order to  
routine biochemical and thyroid hormone checkup. Participants were divided into two groups ;  cases (n=400) and  
controls (n=400). Thyroid hormones were measured by ELISA, and lipid profile parameters were evaluated 
colorimetrically by AutoAnalyzer. Results: There were no significant differences in age and sex distribution 
between the two groups. Among the measured thyroid hormones, TSH was significantly different between the two 
groups (p≤ 0.05). In case of  lipid profile, high-density lipoprotein cholesterol  (HDL-C) was significantly different 
between the two groups (p≤ 0.05). However, no significant differences were observed in the amount of low-density 
lipoprotein cholesterol (LDL-C), triglyceride (TG) and cholesterol (p>0.05). Conclusion: SCH patients, showed a 
decrease in HDL-C. It can be concluded that subclinical hypothyroidism similar to hypothyroidism can cause lipid 
metabolism disturbance. 
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Hypothyroidism is one of the most common 
disorders of the endocrine system which can be 
considered as an autoimmune procedure that reduces 
the function of the thyroid gland. Hypothyroidism 
prevalence in various populations is between 10 to 20 
percent, and after diabetes is suited at the second 
place among endocrine system disorders(1). In the 
course of hypothyroidism, there is a compensatory 
stage wherein the level of TSH (Thyrotropin-
Stimulating Hormone) increases in order to sustain the 
thyroid hormones at the normal levels. At this stage, 
TSH level is 5 - 10 µU/ml, T4 (Thyroxine), and T3 
(Triiodothyronine) are at the normal levels, and 
patients exhibit a slight diagnostic symptoms(2). In the 
subsequent stages, free T4 level drops and TSH 
increases to the levels higher than 10 µU/ml, 
moreover, signs and symptoms emerge rapidly, and 
the disease enters the clinical stage(3). Since 
hypothyroidism at its subclinical stage gradually 
progresses and its signs and symptoms are mild and 
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ambiguous, there are a little attention to disease at 
this stage(4). Clinical hypothyroidism is a risk factor 
for ischemic heart and coronary artery diseases(5). 
Studies have shown that hypothyroidism increases 
the risk of heart attacks in women(6). In subclinical 
hypothyroidism, atherogenic disorders might be 
happened which culminates in Coronary artery 
blockage(7). Coronary artery disease has caused 28 
and 29 percent of the mortality in 1990 and 2001, 
respectively, however, it is predicted that it increases 
to 32.5 percent in 2030(8). According to statistics, 56 
percent of ischemic heart disease and 18 percent of 
strokes caused by high blood cholesterol annually(9).   
There are contradictory findings in previous studies 
concerning the relationship between lipid profile 
disturbance and hypothyroidism at clinical and 
subclinical stages(6, 10, 11). Hence, in this study, our 
aim was to evaluate the lipid profile of individuals 
diagnosed with subclinical hypothyroidism and to 
compare the results with individuals with normal 
thyroid gland function.  
Methods 
Study population. In this case-control study, 
our study population is composed  of individuals 
referred to Neka city hospital in Mazandaran 
province, Iran, between the years 2015 to 2017 for a 
routine  checkup of thyroid hormones and lipid 
profile evaluations. In the subsequent steps, 
according to the clinical outcomes, samples were 
divided into cases with subclinical hypothyroidism 
symptoms and control group with thyroid gland 
normal function. In total, 400 SCH patients (200 
men, and 200 women) and 400 healthy individuals 
(200 men, and 200 women) were selected randomly 
as the case and control groups, respectively. A 
questionnaire was arranged in order to collect 
demographic information such as sex, age, 
medication, smoking, history of cardiovascular 
diseases and experiments results. In this study, 
individuals with the serum TSH levels between 0.39-
6.16 mU/L, and normal levels of thyroid hormone, 
total T4 (4.8-11.6 mU/L) and total T3 (0.39-6.16 
mU/L) without taking any medications were 
considered as patients with subclinical 
hyperthyroidism. Prior to admission to the study, an 
informed consent was obtained from all participants. 
Questionnaires were filled by the medical staff of 
endocrinology section of Neka hospital. This step of 
the study was performed blinded both for the 
participant and the researchers. Fasting venous blood 
(10 ml) was collected from each participant by 
venipuncture.  
Inclusion and Exclusion Criteria.  The criteria 
used in this study for the recruitment of patients, were 
age over 18, ability to give informed consent and 
being nonsmoker. Exclusion criteria included having a 
history of cardiovascular diseases, taking medications 
with the ability to reduce blood cholesterol and 
triglyceride levels, taking medications related to 
thyroid disorders, suffering from any other 
endocrinological disorder, anemia, history of thyroid 
surgery and other surgical operations in the last six 
months. 
Thyroid hormones measurement and lipid 
profile evaluation method. After blood collection, 
tubes were incubated for 30 min at room temperature 
to let the blood samples coagulate, afterward, tubes 
were centrifuged and separated serums samples were 
collected, and stored at -70 °C until later use.   
Cholesterol, HDL-C, and triglyceride levels 
were measured colorimetrically by using Pars Azmoon 
assay Kits (Tehran, Iran) in an autoanalyzer machine 
(Selectra-2, Netherland).  
In order to measure LDL-C levels, Friedewald 
formula (FF) (12) was implemented. However, in 
cases where the triglyceride levels were higher than 
400 mg/dl direct method was used to measure LDL 
levels. Thyroid hormone levels were measured by 
ELISA test using commercially available ELISA kits 
from Pars Azmoon Company (Tehran, Iran).  
Statistical analysis. Statistical analysis was 
performed on SPSS software version 18. All the data 
are presented as mean ± SD. Testing for normality was 
done by Kolmogorov-Smirnov test. T-test and Mann–
Whitney test was used to compare the two groups with 
normal and non-normal distributions, respectively. All 
the Statistical analysis were blind to the experimental 
results and groups categorization. p-Values ≤ 0.05 
were considered as significant. 
Results 
In this study, 800 participants were investigated 
and according to their clinical outcomes were 
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categorized into two groups of cases and controls, 
each contained 400 individuals. Age and sex 
distribution of the studied groups are presented in 
Table 1, and as it is demonstrated, there are no 
significant differences between the two groups 
concerning age and sex (p≥0.05). 
As showed in Table 2 TSH levels are 
significantly different between the two groups 
(p≤0.05), while no significant difference was 
observed in the level of T3 and T4 hormones 
(p≥0.05) In lipid profile evaluations of both groups 
which included HDL-C, LDL-C, TG, and 
cholesterol, no significant differences were observed 
in the measured parameters.  
Discussion 
Our findings demonstrated that there is no 
significant difference in lipid profile between healthy 
individuals and patients with subclinical 
hypothyroidism. The only significant difference 
between the two groups was observed in HDL-C 
levels. Moreover, TSH hormone level was 
significantly different between the two groups.  
Studies have shown that acute administration of 
TSH to individuals with normal thyroids function 
causes disorders in the endothelium of the blood 
vessels and increases the level of CRP, TNFα, 
interleukin-6 and other oxidative stress factors. 
Tehrani et al. showed patients with subacute 
hypothyroidism exhibit a reduction in HDL-C and an 
increase in TG amounts when compared with normal 
individuals.  They also showed that subclinical 
hypothyroidism can be a risk factor for cardiovascular 
disease, since it increases the TSH and TG, and 
reduces HDL-C levels(13). Our study also showed that 
HDL levels reduce in these patients compared to 
normal individuals, however, no significant changes 
were observed in triglyceride and LDL-C levels in 
subclinical hypothyroidism patients. Therefore, it can 
be concluded that one of the subclinical 
hypothyroidism risk factors for cardiovascular disease 
might be the reduction of HDL levels. 
Leonidas et al. have studied the lipid profile and 
the cardiovascular disease risk factors in 
hypothyroidism patients. Their results indicated that 
LDL-C and TG levels increase in these patients 
compared to normal individuals(14). In our study, no 
significant changes were observed in LDL-c and TG 
levels between subclinical hypothyroidism patients 
and healthy controls.  
Studies have indicated that in patients with 
clinical hypothyroidism, cholesterol metabolism 
decreases due to the reduction of cholesterol and LDL 
receptors on the surface of hepatocytes which in return 
increases the serum cholesterol and LDL-C levels and 
reduces HDL-C. In another study, the lipid profile of 
the patients with subclinical hypothyroidism was 
evaluated and it was shown that TG and VLDL-C 
levels were significantly different in these patients 
when compared with normal group. Their study did 
not find any relationship between HDL-C, LDL-C, 









1 Age (Year) 50.73±15.30 47.12±14.95 P>0.05 
2 Sex  
A men 200 200 P>0.05 
B women 200 200 
 
Table2. Association of HbA1C with lipid factors. 








1   TSH)mIU/L(      10.61±6.70 2.3±1.32 P≤0.05⃰ 
2 
  T4      
Total)mg/dl( 





T3       
Total(ng/ml) 




*Values obtained by Mann-Whitney test 
¶Values obtained by T-test 
P value was significant at ≤0.05 
TSH: Thyrotropin-Stimulatin Hormone  
T4: Thyroxine 
T3: Triiodothyronin 
Table3. The lipid profile of case and control groups. 







1 Chol(mg/dl) 196.04±40.85 191.23±48.00 P≥0.05¶ 
2 TG(mg/dl) 187.42±131.87 157.72±82.77 P≥0.05* 
3 LDL(mg/dl) 113.67±33.12 109.66±33.59 P≥0.05¶ 
4 HDL(mg/dl) 42.08±12.06 46.98±10.86 P≤0.05* 
V*Values obtained by Mann-Whitney test 
¶Values obtained by T-test P value was significant at ≤0.05 
 P value was significant at ≤0.05 
Chol: Cholesterol, TG: Triglycerides, HDL: High Density Lipoprotein. LDL: 
Low Density Lipoprotein 
Mann-Whitney test 
¶Values obtained by T-test 
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and cholesterol with hypothyroidism(2). Conversely, 
our study did not find any significant difference in 
TG levels between the patients and healthy controls, 
however, HDL-C level was significantly different 
between the two groups. Guntaka et al  reported that 
cholesterol and LDL-C levels increase in patients 
with subclinical hypothyroidism compared two 
normal individuals. They also stated that increase in 
cholesterol and LDL-C levels can be a risk factor for 
atherosclerosis(15). In the current study, no 
significant differences were observed between the 
patients and healthy controls, but a significant 
reduction in HDL-C level was observed which can be 
considered as an involving factor in cardiovascular 
disease. 
More recently, it was reported that  TG level 
significantly increases in subclinical hypothyroidism 
patients compared to healthy controls, while, they did 
not observe any significant difference in HDL-C 
levels between two groups(16). In contrast to Bayar 
results, our findings indicated that HDL-C 
significantly decreases in patients with subclinical 
hypothyroidism and can be considered as a risk 
factor forcardiovascular disease in these patients.  
Efstathiadou et al. reported that cholesterol, 
LDL and Apolipoprotein A in the lipid profile of 
subclinical hypothyroidism patient differ 
significantly from healthy controls(17). Conversely, 
our study could not report any significant differences 
in LDL-C and cholesterol levels and observed a 
significant decrease in HDL-C level. Inconsistency 
among different studies are very challenging and 
might be as a result of genetic variations, differences 




According to our findings, it can be concluded 
that subclinical hypothyroidism can be considered as 
a possible risk factor for cardiovascular disease. 
Therefore, it is suggested that the lipid profile 
disturbance in subclinical hypothyroidism patients 
should be investigated in more studies and their TSH 
hormone should be evaluated more precisely, since 
the early diagnosis and treatment of such patients 
may prevent progression into clinical hypothyroidism 
and its related complications. 
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